MagVenture Receives FDA Clearance for Accelerated TMS

MagVenture Receives FDA Clearance for Accelerated TMS Protocols, Expanding Flexibility for Clinics and Patients. MagVenture, a global leader in non-invasive neuromodulation technology, has announced that the U.S. Food and Drug Administration (FDA) has granted clearance for an expanded indication of its MagVenture TMS Therapy® system to include accelerated transcranial magnetic stimulation (aTMS) protocols. This clearance introduces a highly flexible treatment paradigm for Major Depressive Disorder (MDD) in adult patients, safely allowing clinicians to deliver multiple TMS sessions per day over a condensed schedule. Redefining the TMS Treatment Timeline. Unlike traditional TMS schedules, which typically involve one session per day over several weeks, accelerated TMS allows for multiple sessions per day. Rapid Completion: Clinicians can administer between 2 to 10 sessions daily based on patient needs, allowing a full course of treatment to be completed in as few as 5 days., Protocol Flexibility: The expanded indication includes accelerated protocols for both repetitive TMS (rTMS) and intermittent theta-burst stimulation (iTBS)., Accessible Implementation: Crucially, this clearance allows accelerated TMS protocols to be delivered using standard scalp-based targeting methods (such as Beam F3 or the 5.5-cm rule) without the strict requirement of MRI or advanced neuronavigation. No Hardware Changes Required. The accelerated clearance is based on the established safety and effectiveness of existing MagVenture TMS Therapy® technology. Clinics currently operating MagVenture systems can adopt these new multi-session protocols without needing to upgrade their hardware, change stimulation output, or alter their safety architecture. Expanding Access to Care. By drastically reducing the time burden on patients, accelerated TMS helps bridge the gap in mental health care. It offers new opportunities to align care delivery with clinic workflows while making effective, non-pharmacological depression treatment more adaptable for patients who cannot commit to a standard multi-week schedule.